453 related articles for article (PubMed ID: 23138014)
21. Ivabradine: new drug. Best avoided in stable angina.
Prescrire Int; 2007 Apr; 16(88):53-6. PubMed ID: 17458043
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris.
Tendera M; Borer JS; Tardif JC
Cardiology; 2009; 114(2):116-25. PubMed ID: 19468225
[TBL] [Abstract][Full Text] [Related]
23. [A possibility to interchange heart rate-slowing therapy with ivabradine and atenolol in patients with stable angina pectoris].
Shavarov AA; Kiiakbaev GK; Kobalava ZhD
Ter Arkh; 2013; 85(4):77-83. PubMed ID: 23808298
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Stable Angina Pectoris With Ivabradine in Everyday Practice: A Pan-Hellenic, Prospective, Noninterventional Study.
Zarifis J; Grammatikou V; Kallistratos M; Katsivas A;
Clin Cardiol; 2015 Dec; 38(12):725-32. PubMed ID: 26782939
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus.
Borer JS; Tardif JC
Am J Cardiol; 2010 Jan; 105(1):29-35. PubMed ID: 20102886
[TBL] [Abstract][Full Text] [Related]
26. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
Tavazzi L; Swedberg K; Komajda M; Böhm M; Borer JS; Lainscak M; Robertson M; Ford I;
Int J Cardiol; 2013 Dec; 170(2):182-8. PubMed ID: 24225201
[TBL] [Abstract][Full Text] [Related]
27. [The comparative effectiveness of beta-blockers and inhibitors of if-iodium using in patients with stable angina pectoris].
Shirokova S; Ilashchuk T; Okipniak I
Georgian Med News; 2015 Mar; (240):25-8. PubMed ID: 25879554
[TBL] [Abstract][Full Text] [Related]
28. Heart rate slowing versus other pharmacological antianginal strategies.
Diaz A; Tardif JC
Adv Cardiol; 2006; 43():65-78. PubMed ID: 16936473
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients.
Nerla R; Di Franco A; Milo M; Pitocco D; Zaccardi F; Tarzia P; Sarullo FM; Villano A; Russo G; Stazi A; Ghirlanda G; Lanza GA; Crea F
Heart; 2012 Dec; 98(24):1812-6. PubMed ID: 23086971
[TBL] [Abstract][Full Text] [Related]
30. Ivabradine in chronic stable angina: Effects by and beyond heart rate reduction.
Camici PG; Gloekler S; Levy BI; Skalidis E; Tagliamonte E; Vardas P; Heusch G
Int J Cardiol; 2016 Jul; 215():1-6. PubMed ID: 27104917
[TBL] [Abstract][Full Text] [Related]
31. Reduction of resting heart rate with antianginal drugs: review and meta-analysis.
Cucherat M; Borer JS
Am J Ther; 2012 Jul; 19(4):269-80. PubMed ID: 21804377
[TBL] [Abstract][Full Text] [Related]
32. Effect of Metoprolol Succinate in Patients with Stable Angina and Elevated Heart Rate Receiving Low-Dose β-Blocker Therapy.
Jiang J; Cong H; Zhang Y; Li Z; Tao G; Li X; Qing L; Tan N; Zhao Z; Dong Y; Ji Z; Chen Y; Ge J; He B; Sun Y; Cao K; Huo Y
Int J Med Sci; 2017; 14(5):477-483. PubMed ID: 28539824
[No Abstract] [Full Text] [Related]
33. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.
Cocco G; Rousseau MF; Bouvy T; Cheron P; Williams G; Detry JM; Pouleur H
J Cardiovasc Pharmacol; 1992 Jul; 20(1):131-8. PubMed ID: 1383622
[TBL] [Abstract][Full Text] [Related]
34. [Antianginal efficacy and tolerability of ivabradine in the therapy of patients with stable angina: results of the CONTROL study].
Glezer MG; Saĭgitov RT
Kardiologiia; 2010; 50(11):65-75. PubMed ID: 21526568
[TBL] [Abstract][Full Text] [Related]
35. Anti-Anginal and Metabolic Effects of Carvedilol and Atenolol in Patients with Stable Angina Pectoris: A Prospective, Randomized, Parallel, Open-Label Study.
Oh PC; Kang WC; Moon J; Park YM; Kim S; Kim MG; Lee K; Ahn T; Shin EK
Am J Cardiovasc Drugs; 2016 Jun; 16(3):221-8. PubMed ID: 27021556
[TBL] [Abstract][Full Text] [Related]
36. Ivabradine in stable coronary artery disease without clinical heart failure.
Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
[TBL] [Abstract][Full Text] [Related]
37. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis.
Danchin N; Marzilli M; Parkhomenko A; Ribeiro JP
Cardiology; 2011; 120(2):59-72. PubMed ID: 22122948
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety and efficacy of ivabradine in patients with chronic stable angina.
López-Bescós L; Filipova S; Martos R
Cardiology; 2007; 108(4):387-96. PubMed ID: 17890862
[TBL] [Abstract][Full Text] [Related]
39. [New opportunities to improve the treatment effectiveness of patients with stable angina].
Grigoryeva NY; Vilkova OE; Samolyuk MO; Kolosova KS
Kardiologiia; 2020 Jul; 60(6):1135. PubMed ID: 32720615
[TBL] [Abstract][Full Text] [Related]
40. [The efficacy and safety of the combination of β-blocker bisoprolol and if inhibitor I(f) ivabradine in patients with stable angina and chronic obstructive pulmonary disease].
Ageev FT; Makarova GV; Patrusheva IF; Orlova IaA
Kardiologiia; 2010; 50(10):22-6. PubMed ID: 21118175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
